Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
stocks
ResMed earnings: Solid showing from ASX healthcare winner
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
stocks
Tesla: Board announces new pay package for CEO Elon Musk
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,028.80 | 106.80 | 1.20% |
CAC 40 | 7,638.82 | 6.81 | 0.09% |
DAX 40 | 23,842.60 | 84.91 | 0.36% |
Dow JONES (US) | 44,173.64 | 42.66 | 0.10% |
FTSE 100 | 9,153.18 | 24.88 | 0.27% |
HKSE | 24,902.53 | 169.08 | 0.68% |
NASDAQ | 21,053.58 | 403.45 | 1.95% |
Nikkei 225 | 40,549.54 | 258.84 | 0.64% |
NZX 50 Index | 12,877.04 | 193.00 | 1.52% |
S&P 500 | 6,329.94 | 91.93 | 1.47% |
S&P/ASX 200 | 8,770.40 | 106.70 | 1.23% |
SSE Composite Index | 3,617.60 | 34.29 | 0.96% |